MHRA approves Efmody (hydrocortisone modified-release hard capsules) for the treatment for congenital adrenal hyperplasia

Congenital adrenal hyperplasia is a rare condition caused by deficiency of adrenal enzymes. Approval of Efmody for this indication was based on the results of a Phase III study (n=122) and an open-label extension.

Source:

PharmaTimes